




**Signatera™**  
Residual disease test (MRD)

# Setting the standard with the most comprehensively validated and widely used MRD assay available



Signatera™ is a highly sensitive and tumor-informed molecular residual disease assay (MRD) using circulating tumor DNA (ctDNA), custom designed for each patient to help inform earlier intervention

## Informing treatment decisions across the continuum of care



## Setting the standard for MRD testing

With this unrivaled clinical validation and experience, clinicians can feel confident with the accuracy and reliability of a Signatera™ result



### Validated performance<sup>1,2</sup>

Across **6,500 patients**, **>30 tumor types**, and **>85 peer-reviewed publications**

Prognostic of disease recurrence and progression; predictive of IO treatment benefit



### Optimized for longitudinal monitoring

Signatera™ **quantifies ctDNA** via mean tumor molecules per mL (MTM/mL) of plasma to **assess real-time changes in disease burden**



### Extensive experience helping power treatment decisions<sup>3</sup>

**>230,000** Signatera™ patients  
**~40%** of US oncologists have ordered Signatera™



### Broadest payer coverage\*

Signatera™ is covered by Medicare for **CRC, ovarian, breast, MIBC, and pan-cancer immunotherapy response monitoring**

**References:** **1.** Bratman SV, Yang SYC, Iafolla MAJ, et al. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. *Nature Cancer*. 2020;1(9):873-881. **2.** Powles T, Assaf ZJ, Davarpanah N, et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. *Nature*. 2021. **3.** Natera data on file \*As of June 2023

Discover more



13011 McCallen Pass, Building A Suite 100 | Austin, TX 78753 | +1 844.778.4700 | natera.com

Signatera™ has been developed and its performance characteristics determined by the CLIA-certified laboratory performing the test. The test has not been cleared or approved by the US Food and Drug Administration (FDA). CAP accredited, ISO 13485 certified, and CLIA certified. © 2024 Natera, Inc. All Rights Reserved. SGN\_AD\_ACCC\_ONC\_FullPage\_November\_20241011\_NAT-8021875

## ONCOLOGY ISSUES

The Journal of the  
Association of Cancer Care Centers

### Editor-in-Chief

Mark Liu, MHA

### Executive Director

Meagan O'Neill, MS

### Managing Editor

Monique J. Marino

### Associate Editors

Nicole Colwell, MD

Rachel Morrison Brown

Rania Emará

Molly Kisiel, MSN, FNP-BC

Rachel Radwan

Emily Wire

### EDITORIAL BOARD

Robert R. Buras, MD

Lindsey Byrne, MS, CGC

Alissa Huston, MD

Heather Jackson, PhD, APRN-BC, NEA-BC, FAANP

Sarah Jax, RN, MA, CNP, AOCNP

Jeffrey Kendall, PsyD

Keri Michalilik, MHA, BSN

Krista Nelson, LCSW, OSW-C, BCD, FAOSW, ACCCC

Emily Touloukian, DO

### ACCC EXECUTIVE COMMITTEE

#### President

Nadine J. Barrett, PhD, MA, MS, FACCC

#### President – Elect

Una Hopkins, RN, FNP-BC, DNP, FACCC

#### Treasurer

Douglas B. Flora, MD, LSSBB, FACCC

#### Secretary

Jorge Garcia, PharmD, MS, MHA, MBA, FACHE, FACCC

#### Immediate Past President

Olalekan Ajayi, PharmD, MBA, FACCC

#### Trustees

Jennifer Bires, MSW, LCSW, OSW-C, FACCC

JiaJoyce Conway, DNP, CRNP, AOCNP

Renea Duffin, MPA

Matthew Manning, MD, FASTRO, FACCC

Lailea Noel, PhD, MSW

Kurt Oettel, MD

Lori Schneider, FACCC

Leigha Senter-Jamieson, MS, LGC

Afreen Idris Shariff, MD, MBBS

Cardinale B. Smith, MD, PhD

*Oncology Issues* serves the multidisciplinary specialty of oncology care and cancer program management.

*Oncology Issues* (ISSN: 1046-3356) is published bimonthly for a total of 6 issues per year by the Association of Cancer Care Centers (ACCC), 1801 Research Blvd, Suite 400, Rockville, MD 20850-3184, USA. Copyright © 2024 by the Association of Cancer Care Centers. All rights reserved. No part of this publication may be reproduced, stored, transmitted, or disseminated in any form or by any means without prior written permission from the publisher.

## FROM THE EDITOR ..... Unleashing Innovation

BY MARK LIU, MHA



As I write my final column as Editor-in-Chief, I am filled with both gratitude and optimism. Serving in this role has been a profound privilege, offering me the opportunity to elevate my voice and share the groundbreak-

ing advancements in oncology that are transforming patient care and outcomes.

Over the past 2 years, we have explored pivotal trends shaping our field, from the integration of artificial intelligence into clinical workflows to the rise of precision medicine and making continued progress for equitable access to care. These developments are not just reshaping how we care for patients with cancer—they are redefining what is possible for patients, families, and caregivers. Reflecting on these themes, I am reminded of the incredible resilience and innovation within our oncology community, particularly recovering from the challenges of a global pandemic, including workforce shortages, supply chain challenges, and clinician and staff burnout, just to name a few.

Looking ahead, the future of cancer care will be driven by those who are unafraid to challenge the status quo and unleash transformative change while navigating uncertainty. It will require us to think outside of the box, innovate responsibly, and maintain our unwavering commitment to the patients we serve. While my time as Editor-in-Chief is now at an end, I am confident that the dialogue we have cultivated here will continue to inspire action and innovation.

Be a part of these critical conversations by applying today for a 2025 ACCC Innovator Award. Now in its 15<sup>th</sup> year, these prestigious awards recognize visionary and compelling ideas in oncology from ACCC Cancer Program Members nationwide. The ACCC Innovator Awards shine a national spotlight on solutions in practice today that advance access, quality, and value in cancer care delivery. Mount Sinai has been awarded 2 ACCC Innovator Awards: the first in 2018 for work done by its dedicated palliative radiotherapy

team and the second in 2023 for the creation of an advanced practice radiation therapist role, so I can personally attest that the experience is a rewarding one. So, do not miss this opportunity to showcase *your* cancer program on a national stage, to unleash the power of positive change, and to inspire others to think differently about cancer care delivery and the patient experience. Apply online today at [innovator.awardsplatform.com](https://innovator.awardsplatform.com). ACCC is accepting applications through February 24, 2025.

In closing, I would like to thank you for allowing me to be part of this journey. I encourage all of you to stay engaged, curious, and collaborative as we work together to shape the next era of cancer care. As always, I look forward to seeing you in person at the [ACCC 51st Annual Meeting & Cancer Center Business Summit](#), March 5-7, in Washington, DC, and at the [ACCC 42nd National Oncology Conference](#), October 15-17, in Denver, Colorado, where we will learn from and celebrate the 2025 ACCC Innovator Award winners. 📺